PT1911458E - Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células - Google Patents

Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células Download PDF

Info

Publication number
PT1911458E
PT1911458E PT70163613T PT07016361T PT1911458E PT 1911458 E PT1911458 E PT 1911458E PT 70163613 T PT70163613 T PT 70163613T PT 07016361 T PT07016361 T PT 07016361T PT 1911458 E PT1911458 E PT 1911458E
Authority
PT
Portugal
Prior art keywords
cell
signal transduction
transduction pathway
peptide inhibitors
permeable peptide
Prior art date
Application number
PT70163613T
Other languages
English (en)
Portuguese (pt)
Inventor
Christophe Bonny
Original Assignee
Xigen Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Inflammation Ltd filed Critical Xigen Inflammation Ltd
Publication of PT1911458E publication Critical patent/PT1911458E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
PT70163613T 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células PT1911458E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/165,250 US20030108539A1 (en) 2000-02-14 2002-06-07 Cell-permeable peptide inhibitors of the JNK signal transduction pathway

Publications (1)

Publication Number Publication Date
PT1911458E true PT1911458E (pt) 2014-05-07

Family

ID=29732060

Family Applications (3)

Application Number Title Priority Date Filing Date
PT80213945T PT2060265E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células
PT06019172T PT1776958E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células
PT70163613T PT1911458E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT80213945T PT2060265E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células
PT06019172T PT1776958E (pt) 2002-06-07 2003-06-09 Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células

Country Status (14)

Country Link
US (1) US20030108539A1 (enExample)
EP (7) EP1970070A3 (enExample)
JP (2) JP4460445B2 (enExample)
AT (2) ATE417623T1 (enExample)
AU (1) AU2003274820B2 (enExample)
CA (1) CA2488695C (enExample)
CY (3) CY1108847T1 (enExample)
DE (2) DE60316149D1 (enExample)
DK (2) DK1911458T5 (enExample)
ES (3) ES2319454T3 (enExample)
HK (1) HK1207971A1 (enExample)
PT (3) PT2060265E (enExample)
SI (1) SI1776958T1 (enExample)
WO (1) WO2003103698A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1661912A1 (en) * 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CA2663545A1 (en) 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof
CN103524623A (zh) 2007-01-19 2014-01-22 凯制药公司 肽组合物的修饰以提高稳定性和递送效率
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US20120101046A1 (en) * 2009-03-30 2012-04-26 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
EP3501521A1 (en) * 2011-02-18 2019-06-26 Otonomy, Inc. Prevention of and recovery from drug-induced ototoxicity
BR112014013041A2 (pt) * 2011-11-30 2019-09-24 Xigen Inflammation Ltd uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
PL3013353T3 (pl) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
GB201719520D0 (en) * 2017-11-24 2018-01-10 Univ College Cardiff Consultants Ltd Neuroprotectvie peptide
CN109182250A (zh) * 2018-09-30 2019-01-11 山东省立医院 一种小鼠耳蜗毛细胞培养方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US817457A (en) * 1906-01-18 1906-04-10 Kelley M Turner Head band or support for telephone-receivers.
US1447969A (en) * 1922-05-12 1923-03-13 Brandes Inc C Telephone head set
US4048453A (en) * 1976-02-11 1977-09-13 Gustave Seidel Telephone handset support device
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
DE4005783A1 (de) * 1990-02-23 1991-09-05 Andreas Suckert Kopfhalterung fuer telefonhoerer
EP0903408A3 (en) * 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
ATE200625T1 (de) 1992-10-09 2001-05-15 Advanced Tissue Sciences Inc Leberreservezellen
EP0767833A1 (en) * 1995-04-25 1997-04-16 Baxter International Inc. Composition containing collagenase and chymopapain for isolating hepatocytes and pancreatic islet cells
BR9610058A (pt) 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
US5689558A (en) * 1996-03-25 1997-11-18 Osgood; Alan G. Telephone handset holder
US5880261A (en) * 1997-04-03 1999-03-09 Waeber; Gerard Transcription factor Islet-Brain 1 (IB1)
US5828749A (en) * 1997-04-04 1998-10-27 Brodskiy; Arkadiy Phone holder kit
US6043083A (en) * 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
EP0897002A3 (en) * 1997-08-14 2001-10-04 Smithkline Beecham Plc U62317, a protein having a JNK-binding domain
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
AU3714499A (en) * 1998-05-14 1999-11-29 Pasteur Merieux Serums Et Vaccins Hepatitis c virus mimotopes
AU755564B2 (en) * 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
WO2000018407A1 (en) * 1998-09-25 2000-04-06 Cephalon, Inc. Methods for preventing/treating damage to sensory hair cells and cochlear neurons
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2392615A1 (en) * 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
ES2386505T3 (es) * 2000-10-17 2012-08-22 Diatranz Otsuka Limited Preparación y xenotrasplante de islotes de cerdo
DE10117281A1 (de) * 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
CA2442909C (en) * 2001-04-06 2011-11-29 Thomas Jefferson University Multimerization of hiv-1 vif protein as a therapeutic target

Also Published As

Publication number Publication date
ES2473274T9 (es) 2015-02-26
ATE417623T1 (de) 2009-01-15
EP1970070A3 (en) 2010-06-02
DE60325429D1 (de) 2009-01-29
CY1114715T1 (el) 2016-10-05
EP1776958A2 (en) 2007-04-25
EP2060265A3 (en) 2010-06-02
HK1111635A1 (en) 2008-08-15
JP4460445B2 (ja) 2010-05-12
EP1911458B1 (en) 2014-03-19
PT1776958E (pt) 2009-02-17
EP1776958B9 (en) 2013-08-14
JP2010053136A (ja) 2010-03-11
EP1970070A2 (en) 2008-09-17
EP2532357A2 (en) 2012-12-12
ATE372125T1 (de) 2007-09-15
DK1911458T3 (da) 2014-04-07
DK1776958T5 (da) 2013-10-21
EP1776958B1 (en) 2008-12-17
ES2319454T9 (es) 2013-11-25
EP1511507B1 (en) 2007-09-05
JP2006501165A (ja) 2006-01-12
PT2060265E (pt) 2013-11-27
DE60316149D1 (de) 2007-10-18
EP2532357A3 (en) 2013-08-14
AU2003274820B2 (en) 2009-01-08
ES2319454T3 (es) 2009-05-07
EP1911458B9 (en) 2014-11-19
SI1776958T1 (sl) 2009-06-30
EP1911458A2 (en) 2008-04-16
CY1115331T1 (el) 2017-01-04
ES2439950T3 (es) 2014-01-27
ES2473274T3 (es) 2014-07-04
CA2488695A1 (en) 2003-12-18
AU2003274820A1 (en) 2003-12-22
CY1108847T1 (el) 2014-07-02
DK1776958T3 (da) 2009-04-06
EP1911458A3 (en) 2008-07-02
EP2060265A2 (en) 2009-05-20
WO2003103698A1 (en) 2003-12-18
HK1207971A1 (en) 2016-02-19
EP2845603A1 (en) 2015-03-11
HK1098961A1 (en) 2007-08-03
DK1911458T5 (da) 2015-01-05
US20030108539A1 (en) 2003-06-12
EP2060265B1 (en) 2013-10-09
EP1776958A3 (en) 2007-12-26
CA2488695C (en) 2011-12-20
EP1511507A1 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
PT1911458E (pt) Inibidores peptídicos da via de transdução de sinal da jnk, permeáveis em células
PT1303600E (pt) Inibidores peptídicos de permeabilidade celular da via de transdução do sinal de jnk
EP1501532A4 (en) PEPTIDE INHIBITORS OF PROTEIN KINASE C
IL189133A0 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
NO20005637L (no) Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav
DK1495128T3 (da) Forstærket proteinekspression i Bacillus
TW200602029A (en) Inhibitors of IAP
WO2003057725A3 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
PL373007A1 (en) Novel antagonists of mcp proteins
EP1416934A4 (en) PROTEIN KINASE INHIBITORS WITH ATP MIMETICS, CONJUGATED TO PEPTIDES OR PEPTIDOMIMETICS
AU2003282338A8 (en) Determination of protein function
WO2005044244A3 (de) Verwendung von mrp4-inhibitoren zur behandlung und/oder prophylaxe kardiovaskulärer erkrankungen
TW200504218A (en) Methods for preventing gluconoylation of proteins
HK1074398A (en) Peptide inhibitors of protein kinase c
HK1075891A (en) Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
AU2003205607A1 (en) Synthetic or partially purified peptides which can bind to specific subunits of g proteins and uses thereof